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Abstract
Background: Trofile® is the prospectively validated HIV-1 tropism assay. Its use is limited by high costs, long turn-
around time, and inability to test patients with very low or undetectable viremia. We aimed at assessing the efficiency 
of population genotypic assays based on gp120 V3-loop sequencing for the determination of tropism in plasma viral 
RNA and in whole-blood viral DNA. Contemporary and follow-up plasma and whole-blood samples from patients 
undergoing tropism testing via the enhanced sensitivity Trofile® (ESTA) were collected. Clinical and clonal 
geno2pheno[coreceptor] (G2P) models at 10% and at optimised 5.7% false positive rate cutoff were evaluated using viral 
DNA and RNA samples, compared against each other and ESTA, using Cohen's kappa, phylogenetic analysis, and area 
under the receiver operating characteristic (AUROC).
Results: Both clinical and clonal G2P (with different false positive rates) showed good performances in predicting the 
ESTA outcome (for V3 RNA-based clinical G2P at 10% false positive rate AUROC = 0.83, sensitivity = 90%, specificity = 
75%). The rate of agreement between DNA- and RNA-based clinical G2P was fair (kappa = 0.74, p < 0.0001), and DNA-
based clinical G2P accurately predicted the plasma ESTA (AUROC = 0.86). Significant differences in the viral populations 
were detected when comparing inter/intra patient diversity of viral DNA with RNA sequences.
Conclusions: Plasma HIV RNA or whole-blood HIV DNA V3-loop sequencing interpreted with clinical G2P is cheap and 
can be a good surrogate for ESTA. Although there may be differences among viral RNA and DNA populations in the 
same host, DNA-based G2P may be used as an indication of viral tropism in patients with undetectable plasma viremia.
Background
Maraviroc (MVC) is the first CCR5 antagonist approved
for the treatment of HIV-1 infection [1] following the
demonstration of its virological efficacy in treatment-
experienced patients [2,3]. There is reasonable expecta-
tion that MVC or other CCR5-antagonists can be even
better administered to treatment-naïve patients due to a
higher prevalence of CCR5-tropic (R5) HIV-1 in this pop-
ulation as compared to more advanced patients [4]. Due
to the lack of virologic activity against CXCR4-tropic
(X4) virus [5], the administration of MVC is subject to the
verification of an R5 virus population in the candidate
patient. The enhanced sensitivity Trofile® assay (ESTA) is
the current gold standard phenotypic method for the
determination of co-receptor tropism for the replicating
viral population (i.e. plasma RNA), although other in-
house or commercial tests are available, some of which
use peripheral blood mononuclear cell (PBMC DNA)
[6,7]. The drawbacks of any phenotypic test include high
costs, long turn-around time, and reduced efficiency in
patients with low viremia. For this reason, there is a
demand for a fast and cheap HIV-1 tropism assay to fully
exploit CCR5 antagonists as a treatment option in clinical
routine [8,9].
Given that most of the determinants of viral co-recep-
tor tropism are based on polymorphisms of the third
hypervariable region (V3) of the gp120, an alternative to
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the phenotypic approach is the usage of machine learning
tools based on viral genotypic information. So called in-
silico or virtual phenotype models may be indeed conve-
nient for clinical practice due to the reduction of costs
and turn-around time. During the recent years, several
prediction models have been studied, from the first sim-
ple rule based on the polymorphisms at V3 codons 11
and 25, to the position specific scoring matrices (PSSM),
neural networks, support vector machines, random for-
ests and logistic models [10-20]. Some of these studies
identified additional factors possibly impacting viral tro-
pism, such as viral subtype and CD4 cell counts
[14,16,20]. Comparisons among genotypic and pheno-
typic tests have been carried out. The genotypic
geno2pheno[coreceptor] system [16] was compared with the
first generation Trofile® and the TRT phenotypic assays
[21], showing 86.5% and 79.7% concordance, respectively.
A study comparing the predictive performance of
geno2pheno[coreceptor], PSSM [12] and other methods
against the first-generation Trofile® assay, concluded that
current default implementations of co-receptor predic-
tion algorithms were inadequate for predicting CXCR4
co-receptor usage in clinical samples, due to inability to
detect low-level X4 virus [22]. Another study found the
concordance among genotype-based predictors and first-
generation Trofile® being as high as 91% [23]. Variable
performance of in-silico models was shown when consid-
ering non-B HIV-1 variants [24-26].
Concerning the clinical validation of phenotypic assays,
another recent work focused on the performance of the
Trofile® test in predicting the virological response to a
short-term maraviroc exposure in HIV-infected patients
[27]. Concomitantly, a few attempts to unveil mutational
patterns associated to selection by CCR5 antagonists or
resistance have been carried out [28,29], but the fre-
quency and rate at which maraviroc resistance mutations
emerge are not yet known.
The most awaited information is how in-silico tropism
prediction models predict virological response to CCR5-
antagonists, particularly when genotypic and phenotypic
results disagree. In fact, although the ESTA should detect
lower amounts of X4 virus compared to bulk genotyping,
the X4 level threshold compromising in vivo CCR5-
antagonist activity in vivo is currently unknown. In addi-
tion, ESTA cannot be performed at low or undetectable
viral load (VL), while HIV-1 DNA genotyping can be eas-
ily performed in such cases; and this information, if ade-
quately validated, might be easily employed for guiding
treatment switches to CCR5 antagonists in virologically
suppressed patients, due to toxicity or simplification
issues. Finally, genotyping can also be used to detect HIV-
1 mutations selected by MVC and possibly decreasing its
effectiveness. Our study aimed at evaluating the accuracy
of HIV-1 co-receptor tropism prediction by viral RNA
and DNA genotyping, as well as the selection of V3
mutants in MVC-failing individuals.
Methods
Patients
Contemporary plasma and whole-blood samples were
prospectively collected from HIV-infected patients fol-
l o w e d  u p  a t  a  s i n g l e  c e n t r e  o f  t h e  I n f e c t i o u s  D i s e a s e s
Clinic of Catholic University of Sacred Heart in Rome,
Italy, all failing antiretroviral treatment and potentially
candidates for treatment with a CCR5-antagonists, in the
period between November 2007 and July 2009 (n = 55).
Some of these patients underwent tropism testing via the
ESTA (n = 51). Follow-up plasma and whole-blood sam-
ples from these patients were also collected, regardless of
MVC treatment.
Viral amplification and sequencing
Plasma RNA and whole-blood DNA were obtained from
citrated blood by spin column extraction (Qiagen,
Hilden, Germany). Plasma underwent 1-hour centrifuga-
tion at 23,000 x g at 4°C to concentrate virus prior to
extraction. Whole blood was used without pre-process-
ing steps. A 419-bp region encompassing the HIV-1
gp120 V3 domain was amplified by (RT)-PCR and
sequenced in both strands by infrared-labelled primers
on a Licor IR2 system. Plasma RNA was reverse tran-
scribed with primer P151 (5'-CTACTTTATATT-
TATATAATTCAYTTCTC-3', coordinates 7661-7689 in
the reference HXB2 genome). The reverse transcription
reaction was run for 30 minutes at 37°C and included 10
μL of RNA extract, 50 mM Tris-HCl (pH 8.3 at 25°C), 75
mM KCl, 10 mM DTT, 3 mM MgCl2, 200μM each dNTP,
200 U ImProm II RT (Promega), 20 U RNasin (Promega)
and 5 pmol primer P151. The cDNA obtained (one third
of the reverse transcription mixture) or blood DNA (1 μg)
extracted from whole-blood was amplified by a nested
PCR protocol using primer P150 (5'-AATGTCAGCA-
CAGTACAATGYACACAT-3', 6945-6971) and P151 in
the outer amplification step and primer LR33 (5'-CAG-
TACAATGTACACATGGAAT-3', 6955-6976) and LR34
(5'-GAAAAATTCCCCTCCACAATT-3', 7353-7373) in
the inner amplification step. Both outer and inner PCR
mixtures contained 50 mM Tris-HCl (pH 9.0 at 25°C), 50
mM KCl, 2 mM MgCl2, 200 μM each dNTP, 1.25 U
GoTaq polymerase (Promega) and 8 pmol each primer.
The cycling profile was 20 seconds at 52°C, 40 seconds at
72°C and 30 seconds at 94°C for both steps but the num-
ber of cycles was 25 in the outer PCR and 32 in the inner
PCR. The final product was sequenced by the IRD700-Prosperi et al. Retrovirology 2010, 7:56
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labelled sense primer IR25 (5'-GCTGTTAAATG-
GCAGTCTAGCAGAA-3', 7011-7035) and the IRD800-
labelled antisense primer IR77 (5'-GAAAAATTCTCCT-
CYACAATTRA-3', 7351-7373) using the DYEnamic
Direct Cycle Sequencing kit with 7-deaza-dGTP (GE
Healthcare). Sequence contigs were assembled by the
DNASTAR SeqMan II version 5.07 module. Only one
PCR product per sample was subjected to standard popu-
lation sequencing, expected to allow detection of minor-
ity species contributing at least 20% of the whole virus
quasispecies.
Sequence analysis: tropism prediction and its evaluation
The geno2pheno[coreceptor] in-silico genotypic tropism pre-
diction system was employed, using both clinical (requir-
ing VL, nadir CD4 and CD8 count) and clonal
interpretations at 10% false positive rate (FPR) [17], and
by considering a clonal interpretation at the optimised
cut off of 5.75% FPR, based on analysis of clinical da ta
from MOTIVATE and MERIT studies [30,31]. Concor-
dances among geno2pheno predictors and ESTA were
assessed by Cohen's kappa statistic [32]. The predictive
ability of the systems was evaluated by receiver operating
characteristic (ROC) analysis [33,34].
The distance between nucleotide V3 sequences was cal-
culated by the maximum composite likelihood [35], over
a multiple alignment obtained via MUSCLE [36]. Phylo-
genetic analysis was performed using the MEGA 4 soft-
ware [37], estimating tree and branch support with a
bootstrapped neighbour-joining method.
Analysis of selection of env mutations by MVC expo-
sure was performed by considering patients with a RNA
sequence before (the closest to the start date) and after
(considering the latest after at least one month of ther-
apy) MVC initiation. Amino acid mutations were
extracted by local pairwise alignments against the HXB2
reference sequence. Fisher's exact test on frequency
counts of individual mutations and pre- post-MVC strata
was executed; obtained p-values were also corrected with
Benjamini-Hochberg procedure.
The R mathematical programming suite was used to
perform all statistical analyses [38].
Results
Study population and samples
We processed 178 samples (99 plasma RNA and 79
whole-blood DNA) and successfully amplified 155 sam-
ples [78 (78.8%) plasma RNA and 77 (97.5%) whole-blood
DNA] from 55 patients. By stratifying for contemporary
VL, the rate of successful sequencing from RNA was 40%,
88.2%, and 96.2% at < = 50 cp/ml, 51-500 cp/ml, and >500
cp/ml respectively. The rate of successful sequencing
from DNA was 95.1%, 100%, and 100% at < = 50 cp/ml,
50-500 cp/ml, and >500 cp/ml, respectively.
Fifty-one of the 55 patients had their baseline plasma
tested by ESTA, and 28 were subsequently administered
MVC. Patients' baseline characteristics are summarized
in Table 1.
In a cross sectional crude analysis, using dichotomized
ESTA results (R5-tropic versus X4- plus dual/mixed-
tropic), we did not find any significant association with
contemporary patients characteristics, except for the
time from HIV-1 diagnosis [median (IQR) 16 years (13-
18) for R5, and 18 years (17-22) for X4 or dual/mixed-
tropic isolates p = 0.007], and nadir CD4 count [median
(IQR) 138 cells/mm3 (31-200) for R5 and 14 cells/mm3
(6-41) for X4 or dual/mixed-tropic isolates p = 0.05].
Comparison between geno2pheno[coreceptor] classification of 
plasma HIV-1 RNA, DNA V3 sequences and ESTA tropism 
results
We first compared the prediction performance of
geno2pheno versus the ESTA result. For this analysis, we
excluded samples not reportable by ESTA. To match
geno2pheno categories, the dual/mixed virus classifica-
tion by ESTA was pooled with the X4 virus classification.
Figure 1 depicts ROC plots with the performance of two
RNA-based geno2pheno models predicting the ESTA X4
or dual/mixed tropism. Using nucleotide V3 loop
sequences obtained from RNA samples contemporary to
ESTA testing (n = 35), the resulting area under the ROC
curve (AUROC) was 0.83 for geno2pheno clinical inter-
pretation, 0.67 for geno2pheno clonal interpretation at
10% FPR, and 0.75 using the optimised 5.75% FPR cutoff.
When comparing differences in AUROC with respect to
the clinical interpretation reference, neither the clonal
interpretation at 10% FPR nor that at 5.75% FPR cutoff
exhibited a statistically significant lower area (p = 0.17
and p = 0.48, respectively).
As a second performance test, we obtained
geno2pheno tropism predictions for V3 sequences
obtained from DNA samples (n = 17, with 16 sequences
from patients with contemporary RNA genotyping). The
resulting prediction of ESTA X4-D/M tropism showed an
AUROC of 0.86 using geno2pheno clinical interpretation,
0.69 using the geno2pheno clonal interpretation at 10%
FPR, and 0.76 using the optimised 5.75% FPR cutoff (Fig-
ure 2). We did not find significant differences in AUROC
when comparing either the clonal interpretation (p =
0.34) at 10% FPR or that at 5.75% FPR cutoff (p = 0.58)
against the clinical geno2pheno interpretation at 10%
FPR.
Table 2 shows accuracy, sensitivity and specificity of the
clinical, and clonal interpretation at 10% or 5.75% FPR
cutoff of RNA/DNA geno2pheno interpretation modes in
predicting ESTA X4-D/M-tropism.Prosperi et al. Retrovirology 2010, 7:56
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Table 1: Patients' characteristics at the time of ESTA
No. of patients with available ESTA result 51
ESTA results, n (%) CCR5-tropic 31 (61%)
Dual/Mixed-tropic 12 (23%)
CXCR4-tropic 1 (2%)
Not Reportable 7 (14%)
Descriptive total CCR5-tropic Dual/Mixed/CXCR4-tropic
Female gender, n (%) 16 (31%) 12 (39%) 4 (31%)
Mean age (SD) 45 (9) 46 (8) 40 (12)
Median time from HIV-1 diagnosis, years (IQR) 17 (14-19) 16 (13-18) 18 (17-22)
Italian nationality, n (%) 48 (94%) 29 (93%) 12 (92%)
Risk Factor, n (%) Heterosexual 15 (29%) 11 (35%) 3 (23%)
Homosexual/Bisexual 17 (33%) 11 (35%) 4 (31%)
IDU 14 (27%) 7 (23%) 3 (23%)
Other/Unknown 5 (10%) 2 (6%) 3 (23%)
CDC stage, n (%) A 16 (32%) 11 (35%) 3 (25%)
B 10 (20%) 9 (29%) 1 (8%)
C 24 (48%) 11 (35%) 8 (67%)
History of mono-dual NRTI therapy, n (%) 37 (72%) 24 (77%) 10 (77%)
Median duration of ART exposure, years (IQR) 14 (11-16) 13 (11-16) 13 (11-15)
No. of drug switches (any change or interruption) 
experienced (IQR)
13 (9-16) 13 (9-15) 11 (7-15)
Patients previously exposed to 
drug class, n (%)
NRTI 50 (98%) 31 (100%) 13 (100%)
NNRTI 44 (86%) 29 (93%) 10 (77%)
Unboosted PI 49 (96%) 30 (97%) 13 (100%)Prosperi et al. Retrovirology 2010, 7:56
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Comparison of HIV-1 V3 RNA and DNA sequence 
population and their inferred coreceptor tropisms
The median intrapatient distance among HIV RNA or
DNA sequences was, as expected, significantly smaller
than the interpatient distance (see Additional files 1 and
2). However, the intrapatient variability with RNA (0.007)
or with DNA (0.015) sequences was significantly lower
than the intrapatient variability between RNA and DNA
sequences (0.023), suggesting that the HIV-1 V3 DNA
and RNA populations may contribute different informa-
tion and complement each other in a patient. Phyloge-
netic analysis revealed that clusters of sequences with
high support values (bootstrap >90%) corresponded to
sequences drawn from the same patients, and there were
no clusters composed of sequences from different
patients. Clusters were preferentially (but not exclusively)
composed of either paired RNA or DNA samples (phylo-
genetic tree is available as Additional file 1).
We next investigated whether a certain degree of intra-
patient diversity between DNA and RNA populations
results in a different co-receptor tropism prediction.
When comparing geno2pheno clinical interpretation
based on paired HIV-1 V3 DNA-RNA sequences
obtained from 29 distinct patients, we observed 35/40
(87.5%) concordant predictions, 3/40 (7.5%) false posi-
tives, and 2/40 (5%) false negatives, using RNA-predicted
X4-tropism as the reference outcome. The kappa statis-
tics yielded a strength of agreement of 0.74 (95% CI: 0.53-
0.95), with a Fisher's p-value < 0.0001. The AUROC
obtained by predicting the geno2pheno RNA tropism
from contemporary DNA sequences was 0.875.
Viro-immunological follow up
Out of 28 patients with an R5-tropic virus by ESTA sub-
sequently starting MVC, 22 had an available virological
follow up at 12 weeks. All patients had a VL below 50 cp/
ml, except two patients with 120 and 292 cp/ml. Virologi-
cal follow-up at 24 weeks was available for 19 patients. All
of these had a VL below 50 cp/ml, except two patients
(different from those at three months) with a VL of 2,003
and 88 cp/ml.
Immunological follow-up at 12 weeks was available for
20 out of the 28 patients that started MVC. The median
(IQR) CD4 increase was 84 (range -9 to 165) cells/mm3.
A Wilcoxon test showed that this increase from baseline
was statistically significant (p = 0.019). After 24 weeks of
therapy, immunological follow-up was available for 19
patients. The median (IQR) CD4 increase was 46 (-9 to
143) cells/mm3(p = 0.053).
Evolution of V3 sequences during MVC therapy
Finally, we executed statistical tests for difference in pro-
portions by looking at the whole set of mutations
retrieved in the RNA samples with respect to HIV-1
HXB2 envelope reference, grouping sequences in pre-
and post-MVC initiation (n = 18, 9 sequences pre-MVC,
9 post-MVC). Of the 9 pre-MVC sequences (all R5 by
ESTA), 4 (44%) were classified as X4 by clinical
geno2pheno interpretation, with FPR of 4.8%, 7.8%, 0.2%,
and 0.8%. Tropism prediction did not change for any
patient when considering post-MVC samples. No substi-
tution was significantly associated with MVC exposure
by correcting test statistics with Benjamini Hochberg (all
p-values = 1) nor retaining raw unadjusted p-values;
nonetheless a deletion at position 354, mutation 355K,
369L, and 259Q (all in the V3 loop) showed an increase in
prevalence after MVC initiation. Figure 3 depicts muta-
tions detected in the V3 loop in pre- and post-MVC sam-
ples with the lowest unadjusted p-values.
Discussion
In the present study, viral tropism prediction by the HIV-
1 gp120 V3-loop RNA genotype-based geno2pheno[core-
ceptor]  interpretation in treatment-experienced subjects
proved to be a valid alternative to ESTA tropism, yielding
an AUROC of 0.83 using the clinical interpretation. The
clonal interpretation showed a lower AUROC, although
the difference with the clinical interpretation showed
only a trend, probably due to the limited sample size. The
geno2pheno[coreceptor] website suggests that only the clonal
interpretation should be used for treatment-experienced
patients, since the clinical system was trained only on
treatment-naïve patients. However, our results show that
the clinical interpretation is better (at least not inferior)
than the clonal interpretation even in treatment-experi-
enced patients. It is important to highlight the fact that
Boosted PI 35 (69%) 22 (71%) 8 (61%)
CD4 count, median cells/mm3 (IQR) 334 (182-535) 387 (214-464) 211 (198-518)
HIV-1 RNA load, median log10 cp/ml (IQR) 3.66 (2.55-4.30) 3.9 (3.6-4.1) 4.2 (4.0-4.8)
CD4 count at nadir, median cells/mm3 (IQR) 64 (18-191) 138 (31-200) 14 (6-41)
HIV-1 RNA load at zenith, median Log10 cp/ml (IQR) 5.3 (4.6-5.7) 5.5 (4.8-5.7) 5.4 (4.5-5.6)
Table 1: Patients' characteristics at the time of ESTA (Continued)Prosperi et al. Retrovirology 2010, 7:56
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the clinical interpretation needs contemporary VL, nadir
CD4 and CD8 information in order to work properly.
Interestingly, the clinical mode improved sensitivity
much more than specificity with respect to the clonal
mode. The sensitivity of V3 RNA genotyping followed by
clonal geno2pheno[coreceptor]  interpretation has been
recently shown to increase by testing multiple aliquots of
the plasma RNA extract [39], likely as a consequence of
stochastic fluctuations of a minority X4 populations.
Although repeated testing has not yet been established as
a standard procedure, it is expected that its implementa-
tion would result in a higher concordance between tro-
pism results obtained by V3 genotyping and the reference
ESTA.
Another area under investigation is the optimal FPR to
use with geno2pheno[coreceptor] as a cut-off for classifica-
t i o n  o f  R 5  a n d  X 4 - D / M  v i r u s e s .  R e c e n t  r e t r o s p e c t i v e
analysis of the MERIT trial data indicated that the most
accurate FPR cutoff may be in the range from 2% to
5.75%, when triplicate PCR testing and fully automated
sequencing is used [30]. However, there is currently no
consensus on which cut-off to use in clinical practice. As
for any classification test aimed at orienting a clinical
intervention, the trade-off between specificity and sensi-
Figure 1 Area under the ROC curves (AUROC) comparing predictions from RNA samples using geno2pheno clinical (AUROC = 0.83) at 10% 
FPR, geno2pheno clonal (AUROC = 0.67) at 10% FPR, and clonal at 5.75% FPR cutoff (AUROC = 0.75) interpretation modes versus the ESTA 
result (n = 35).Prosperi et al. Retrovirology 2010, 7:56
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tivity must be taken into account. A higher cut-off such as
the 10% FPR was originally proposed [17] and is still rec-
ommended by the expert panel developing and maintain-
ing the geno2pheno[coreceptor]  system (see the German
recommendations [40]). Using a higher cut-off translates
into a conservative attitude, i.e. a lower probability to
treat with maraviroc patients who may not benefit from
it, at the expense of a higher probability not to treat
patients who may benefit from the drug. It remains to be
established whether this lower cut-off can be clinically
more convenient in the genotypic screening of the gen-
eral HIV patient population candidate to treatment with
maraviroc.
One major advantage with genotyping is that even
patients with non-reportable ESTA can be given predic-
tion of tropism. By definition, ESTA is subject to a larger
proportion of failures with respect to genotype due to
virus polymorphisms invalidating the cloning procedure
and an inherently lower rate of reverse transcription of a
far larger virus genome region. Moreover, our efficiency
of RNA genotyping at VL between 50 and 500 cp/ml
(where ESTA is not even attempted) was 88%, whilst that
of DNA genotyping was 100% at these viral loads.
Figure 2 Area under the ROC curve (AUROC) comparing predictions of geno2pheno clinical (AUROC = 0.86) at 10% FPR, geno2pheno clon-
al (AUROC = 0.69) at 10% FPR, and clonal at 5.75% FPR cutoff (AUROC = 0.76) interpretation modes versus the ESTA result, using sequences 
obtained from contemporary DNA samples (n = 17).Prosperi et al. Retrovirology 2010, 7:56
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Interestingly, in-silico tropism prediction using whole-
blood DNA genotyping may be a solution when consider-
ing treatment switch to a CCR5-antagonists for patients
with undetectable viral load. The perspective for treat-
ment switches in these patients may be attractive,
because of the good tolerability of MVC and because
patients that are not at a late stage of disease are more
likely to harbour a CCR5- rather than a CXCR4-tropic
virus [4]. In these cases ESTA cannot be used, and RNA
genotyping is often not sufficiently efficient. The perfor-
mance of DNA-based clinical geno2pheno in predicting
the ESTA result was comparable to that of RNA-based
clinical geno2pheno (AUROC = 0.86). Thus, the use of
V3 DNA sequence data for predicting co-receptor tro-
pism definitely warrants further investigation as an
appealing alternative to RNA.
As expected, we found some differences when compar-
ing paired DNA and RNA sequences, consistent with the
notion that the archived population may not correspond
to the most prevalent virus in plasma, whose source are
the productively infected cells. However, when compar-
ing DNA and RNA tropism prediction by looking at con-
temporary samples, the degree of agreement was good,
implying that such minor differences may not commonly
translate into inappropriate indications. It remains to be
established whether an X4 virus population detected in
PBMC DNA in the context of R5 virus in plasma RNA
can impair response to maraviroc. Although reported on
a limited number of cases, this did not appear to be the
case in the French GenoTropism study [41,42].
Conclusion
HIV-1 tropism determination via plasma viral V3 RNA
genotyping coupled with geno2pheno interpretation may
represent a valid alternative to ESTA. The clinical valida-
tion of genotypic determination of viral tropism has been
recently performed using retrospective samples from the
MOTIVATE study [40] as well as in the GenoTropism
study where the genotypic tropism test was able to pre-
dict response to maraviroc even in the group of patients
with an R5 virus population as detected by standard Tro-
file® [41,42]. As shown here, RNA tropism genotyping car-
ries the advantage of a higher efficiency of tropism
determination in patients with low copy number detect-
able viral loads. In addition to that, in perspective, DNA-
based tropism prediction could be used in patients with
undetectable VL who are candidates for treatment sim-
plification/switch to a CCR5-antagonist. This option can
support a more effective use of this class of agents at ear-
lier stages when the probability of harbouring an R5 virus
population is maximal. However, further investigations to
unveil the evolutionary relationships between DNA and
RNA populations are advisable before DNA genotyping
can be indicated in clinical practice. In this context, ultra-
deep sequencing studies may be appropriate to dissect
the dynamics and role of DNA and RNA minority vari-
ants [43,44]. Most importantly, clinical validation of the
use of HIV-1 genotyping, particularly with proviral DNA,
for tropism assignment is also required before its wide-
spread implementation.
Table 2: Performance evaluation of ESTA X4-dual/mixed tropism prediction using geno2pheno clinical and clonal at 10% 
FPR, or the clonal at the optimised 5.75% FPR interpretation of contemporary viral gp120 V3 DNA or RNA genotyping
Viral sample geno2pheno 
interpretation 
mode (FPR)
AUROC accuracy sensitivity specificity
plasma RNA (n = 35) Clinical (10%) 0.83 80.0% 90.9% 75.0%
Clonal (10%) 0.67 71.4% 54.5% 79.2%
Clonal optim. 
(5.75% )
0.75 82.9% 54.5% 95.8%
whole-blood DNA (n = 17) Clinical (10%) 0.86 76.5% 100% 71.4%
Clonal (10%) 0.69 70.6% 66.7% 71.4%
Clonal optim. 
(5.75% )
0.76 82.3% 66.7% 85.7%Prosperi et al. Retrovirology 2010, 7:56
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